IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v90.6.2188.2188_2188_2195PMID 9310469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

  1996cited by this paper
• Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.

  1996cited by this paper
• A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.

  1996cited by this paper
• Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

  1996cited by this paper
• Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.

  1995cited by this paper
• Phase I Trial of an Anti‐CD19 Deglycosylated Ricin A Chain Immunotoxin in Non‐Hodgkin's Lymphoma: Effect of an Intensive Schedule of Administration

  1995cited by this paper
• Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

  1995cited by this paper
• Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

  1994cited by this paper
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994cited by this paper
• 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.

  1994cited by this paper
• Treatment approaches to the low-grade lymphomas.

  1994cited by this paper
• Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma.

  1994cited by this paper
• CD20: a regulator of cell-cycle progression of B lymphocytes.

  1994cited by this paper
• Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.

  1993cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.

  1993cited by this paper
• A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.

  1993cited by this paper
• Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.

  1992cited by this paper
• 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

  1992cited by this paper
• Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.

  1992cited by this paper
• Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

  1992cited by this paper
• Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon.

  1989cited by this paper
• Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.

  1987cited by this paper
• Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes

  1986cited by this paper
• Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma.

  1986cited by this paper
• A clinical trial of anti-idiotype therapy for B cell malignancy.

  1985cited by this paper
• Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.

  1984cited by this paper
• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.

  1982cited by this paper
• Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

  1982cited by this paper
• National cancer institute sponsored study of classifications of non‐hodgkin's lymphomas. Summary and description of a working formulation for clinical usage

  year unknowncited by this paper

• R-CHOP for non-Hodgkin lymphoma: Its effects on cancer cells, NK cell viability and cytotoxicity against B-lymphoma cell lines

  2026cites this paper
• Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia

  2026cites this paper
• Cognitive impairment is associated with altered blood cell profiles in aggressive lymphoma

  2026cites this paper
• Efficacy and safety of rituximab in Chinese patients of glomerular kidney diseases: An observational study

  2025cites this paper
• JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025

  2025cites this paper
• Emerging role of Rituximab in adult minimal change disease: a narrative review of clinical evidence, biomarkers and future perspectives

  2025cites this paper
• Risk factors and clinical consequences of rituximab infusion-related reactions

  2025cites this paper
• Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential

  2025cites this paper
• Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?

  2025cites this paper
• Hypogammaglobulinemia in Children Receiving Targeted Immunotherapies for B Lineage Malignancies: Practical Guidance for Assessment and Management

  2025cites this paper
• The Transformation of Cancer Nursing Propelled by Novel SACT.

  2025cites this paper
• Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders

  2025cites this paper
• Long-Term Adverse Events of Rituximab in Multiple Sclerosis Patients, Isfahan, Iran

  2025cites this paper
• Technological advancements in antibody-based therapeutics for treatment of diseases

  2025cites this paper
• The Precision Revolution in Hematologic Malignancies: A Decade of Transformative Immunotherapies and Targeted Agents

  2025cites this paper
• Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions

  2025cites this paper
• In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab

  2024cites this paper
• Single‐Batch Expression of an Experimental Recombinant Snakebite Antivenom Based on an Oligoclonal Mixture of Human Monoclonal Antibodies

  2024cites this paper
• Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists

  2024cites this paper
• SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody

  2024cites this paper
• Transcriptome analysis reveals a role of FOXO3 in antileukemia/lymphoma properties of panduratin A

  2024cites this paper
• NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy

  2024cites this paper
• B7-H3 in glioblastoma and beyond: significance and therapeutic strategies

  2024cites this paper
• Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology

  2024cites this paper
• Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective.

  2024cites this paper
• The function of antibodies

  2024cites this paper
• Editorial: Non-cellular immunotherapies in pediatric malignancies

  2024cites this paper
• Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study

  2024cites this paper
• PLL-g-PEG Polymer Inhibits Antibody-Drug Conjugate Uptake into Human Corneal Epithelial Cells In Vitro

  2024cites this paper
• Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies

  2024cites this paper
• A Brief Chronicle of Antibody Research and Technological Advances

  2024cites this paper
• Binding Promiscuity of Therapeutic Factor VIII

  2024cites this paper
• Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis

  2024cites this paper
• The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer.

  2024cites this paper
• Very low doses of rituximab in autoimmune hemolytic anemia—an open-label, phase II pilot trial

  2024cites this paper
• Novel therapies in CIDP

  2024cites this paper
• A Comprehensive Review of the Mechanisms and Clinical Development of Monoclonal Antibodies in Cancer Therapy.

  2024cites this paper
• Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective

  2024cites this paper
• Linking Effector Function to Antitumor Monoclonal Antibody Efficacy.

  2024cites this paper
• Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma

  2024cites this paper
• Enhancing Fc‐mediated effector functions of monoclonal antibodies: The example of HexaBodies

  2024cites this paper
• Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

  2023cites this paper
• Trends in non‐Hodgkin lymphoma mortality rate in Japan and the United States: A population‐based study

  2023cites this paper
• CAR-T cells, the first pharmaceutical cell therapy.

  2023cites this paper
• Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress

  2023cites this paper
• Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.

  2023cites this paper
• Functional Validation of the RQR8 Suicide /Marker Gene in CD19 CAR-T Cells and CLL1CAR-T Cells

  2023cites this paper
• Antibody‐mediated phagocytosis in cancer immunotherapy

  2023cites this paper
• Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis

  2023cites this paper
• Hypogammaglobulinemia secondary to B-cell depleting therapies in neuroimmunology: Comparing management strategies

  2023cites this paper
• The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab

  2023cites this paper
• CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration

  2023cites this paper
• Immunotargeting of Cancer Stem Cells

  2023cites this paper
• A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity

  2023cites this paper
• Support for Removing Pharmacodynamic and Clinical Efficacy Testing of Biosimilars: A Critical Analysis

  2023cites this paper
• Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape

  2023cites this paper
• Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial)

  2023cites this paper
• Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer

  2023cites this paper
• Pan‐cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy

  2023cites this paper
• Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin’s Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study

  2023cites this paper
• The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars

  2023cites this paper
• Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review

  2023cites this paper
• A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

  2022cites this paper
• Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas

  2022cites this paper
• Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.

  2022cites this paper
• New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?

  2022cites this paper
• The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma

  2022cites this paper
• An updated view of the pathogenesis of steroid-sensitive nephrotic syndrome

  2022cites this paper
• Targeted Therapy in Leukaemia, Lymphoma and Myeloma

  2022cites this paper
• schedule of rituximab. Infusion Reactions: Diagnosis,

  2022cites this paper
• The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody

  2022cites this paper
• High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand

  2022cites this paper
• Advancements in Cancer Immunotherapies

  2022cites this paper
• A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.

  2022cites this paper
• A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy

  2022cites this paper
• Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options

  2022influential citation
• Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

  2022influential citation
• Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences

  2022cites this paper
• Off-Label Uses of Rituximab in Dermatology

  2022cites this paper
• Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.

  2022cites this paper
• The global landscape of approved antibody therapies

  2022cites this paper
• MYC and therapy resistance in cancer: risks and opportunities

  2022cites this paper
• Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review

  2022cites this paper
• MONOCLONAL ANTIBODIES IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMAS

  2022cites this paper
• The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics

  2022cites this paper
• Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review

  2022cites this paper
• Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder

  2022cites this paper
• Development of Cancer Immunotherapies.

  2022cites this paper
• Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch

  2022cites this paper
• Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting

  2022cites this paper
• Targeted Liposomes: A Nonviral Gene Delivery System for Cancer Therapy

  2022cites this paper
• Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab

  2022cites this paper
• Liposomes in the Targeted Gene Therapy of Cancer: A Critical Review.

  2022cites this paper
• Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses

  2022cites this paper
• Prognostic factors of severe pneumonia in patients treated with rituximab in the intensive care unit

  2022cites this paper
• Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options

  2022influential citation
• Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile

  2021cites this paper
• Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets

  2021cites this paper
• Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs

  2021cites this paper
• Rituximab for non-infectious Uveitis and Scleritis

  2021cites this paper